{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:08:49Z","timestamp":1790431729454,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.seizure.2018.04.006","type":"journal-article","created":{"date-parts":[[2018,4,14]],"date-time":"2018-04-14T11:55:03Z","timestamp":1523706903000},"page":"96-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Effects of UGT2B7, SCN1A and CYP3A4 on the therapeutic response of sodium valproate treatment in children with generalized seizures"],"prefix":"10.1016","volume":"58","author":[{"given":"Weixing","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghui","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoqin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2018.04.006_bib0005","article-title":"Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug","author":"Tomson","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2018.04.006_bib0010","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra1004418","article-title":"Drug-resistant epilepsy","volume":"365","author":"Kwan","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.seizure.2018.04.006_bib0015","first-page":"42","article-title":"An association between the FABP2 gene polymorphism and efficacy of valproates","volume":"107","author":"Aksenova","year":"2007","journal-title":"Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova"},{"key":"10.1016\/j.seizure.2018.04.006_bib0020","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.seizure.2018.04.006_bib0025","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/epi.13011","article-title":"Clinical significance of CYP2C9-status guided valproic acid therapy in children","volume":"56","author":"Budi","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.04.006_bib0030","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/pgs.11.64","article-title":"Association of genetic variants in six candidate genes with valproic acid therapy optimization","volume":"12","author":"Hung","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.seizure.2018.04.006_bib0035","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2133\/dmpk.DMPK-11-NT-144","article-title":"Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy","volume":"27","author":"Guo","year":"2012","journal-title":"Drug Metab Pharm"},{"key":"10.1016\/j.seizure.2018.04.006_bib0040","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/FTD.0000000000000271","article-title":"Effects of UGT2B7 genetic polymorphisms on serum concentrations of valproic acid in chinese children with epilepsy comedicated with lamotrigine","volume":"38","author":"Wang","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2018.04.006_bib0045","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00228-009-0712-x","article-title":"Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling","volume":"65","author":"Jiang","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2018.04.006_bib0050","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1755-5949.2012.00336.x","article-title":"ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients","volume":"18","author":"Qu","year":"2012","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.seizure.2018.04.006_bib0055","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1056\/NEJMoa021986","article-title":"Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1","volume":"348","author":"Siddiqui","year":"2003","journal-title":"New Engl J Med"},{"key":"10.1016\/j.seizure.2018.04.006_bib0060","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/FPC.0b013e3283498131","article-title":"Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy","volume":"21","author":"Ufer","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.seizure.2018.04.006_bib0065","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12883-017-0801-x","article-title":"Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysis","volume":"17","author":"Chouchi","year":"2017","journal-title":"BMC Neurol"},{"key":"10.1016\/j.seizure.2018.04.006_bib0070","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.seizure.2011.04.003","article-title":"Lack of association of ABCB1 haplotypes on five loci with response to treatment in epilepsy","volume":"20","author":"Haerian","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2018.04.006_bib0075","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jocn.2016.10.014","article-title":"The ABCC2 c. \u221224C\u202f>\u202fT polymorphism increases the risk of resistance to antiepileptic drugs: a meta-analysis","volume":"37","author":"Qian","year":"2017","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.seizure.2018.04.006_bib0080","first-page":"416","article-title":"ABCB1, ABCC2, SCN1A, SCN2A, GABRA1 gene polymorphisms and drug resistant epilepsy in the Chinese Han population","volume":"70","author":"Zhou","year":"2015","journal-title":"Pharmazie"},{"key":"10.1016\/j.seizure.2018.04.006_bib0085","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrn1430","article-title":"The neurobiology of antiepileptic drugs","volume":"5","author":"Rogawski","year":"2004","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.seizure.2018.04.006_bib0090","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.seizure.2010.02.009","article-title":"Association of alpha subunit of GABAA receptor subtype gene polymorphisms with epilepsy susceptibility and drug resistance in north Indian population","volume":"19","author":"Kumari","year":"2010","journal-title":"Seizure"},{"issue":"8","key":"10.1016\/j.seizure.2018.04.006_bib0095","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1007\/s12035-015-9457-y","article-title":"Contribution of GABRG2 polymorphisms to risk of epilepsy and febrile seizure: a multicenter cohort study and meta-analysis","volume":"53","author":"Haerian","year":"2016","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.seizure.2018.04.006_bib0100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.seizure.2012.10.007","article-title":"GABRG2 rs211037 polymorphism and epilepsy: a systematic review and meta-analysis","volume":"22","author":"Haerian","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2018.04.006_bib0105","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/FPC.0000000000000000","article-title":"GABRG2, rs211037 is associated with epilepsy susceptibility, but not with antiepileptic drug resistance and febrile seizures","volume":"23","author":"Balan","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.seizure.2018.04.006_bib0110","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/j.1528-1167.2010.02640.x","article-title":"Sodium channel SCN1A and epilepsy: mutations and mechanisms","volume":"51","author":"Escayg","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.04.006_bib0115","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy","volume":"16","author":"Loscher","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2018.04.006_bib0120","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eplepsyres.2016.02.013","article-title":"Concentrations of carbamazepine and carbamazepine-10,11-epoxide in maternal and umbilical cord blood at birth: influence of co-administration of valproic acid or enzyme-inducing antiepileptic drugs","volume":"122","author":"Kacirova","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2018.04.006_bib0125","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.04.006_bib0130","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005\u20132009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.04.006_bib0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.yebeh.2011.02.015","article-title":"Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy","volume":"21","author":"Meng","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2018.04.006_bib0140","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/FTD.0000000000000337","article-title":"Effects of UGT1A6 and GABRA1 on standardized valproic acid plasma concentrations and treatment effect in children with epilepsy in China","volume":"38","author":"Feng","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2018.04.006_bib0145","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.eplepsyres.2006.10.004","article-title":"The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish population","volume":"73","author":"Shahwan","year":"2007","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2018.04.006_bib0150","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.04.006_bib0155","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-4939-6442-0_5","article-title":"The MassARRAY(R) system for targeted SNP genotyping","volume":"1492","author":"Ellis","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.seizure.2018.04.006_bib0160","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nprot.2010.182","article-title":"Basic statistical analysis in genetic case-control studies","volume":"6","author":"Clarke","year":"2011","journal-title":"Nat Protoc"},{"issue":"Suppl. 2","key":"10.1016\/j.seizure.2018.04.006_bib0165","first-page":"25","article-title":"Pharmacokinetics, drug interactions, and tolerability of valproate","volume":"37","author":"DeVane","year":"2003","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.seizure.2018.04.006_bib0170","doi-asserted-by":"crossref","first-page":"e5332","DOI":"10.1097\/MD.0000000000005332","article-title":"Genetic polymorphisms of CYP3A4 among Chinese patients with steroid-induced osteonecrosis of the femoral head","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.seizure.2018.04.006_bib0175","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/jat\/bku091","article-title":"Fatal methadone toxicity: potential role of CYP3A4 genetic polymorphism","volume":"38","author":"Richards-Waugh","year":"2014","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.seizure.2018.04.006_bib0180","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eplepsyres.2015.09.001","article-title":"Effects of CYP3A4\/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy","volume":"117","author":"Wang","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2018.04.006_bib0185","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1177\/0091270004269142","article-title":"Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital","volume":"44","author":"Hariparsad","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2018.04.006_bib0190","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.seizure.2011.01.008","article-title":"Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy","volume":"20","author":"Haerian","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2018.04.006_bib0195","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.biochi.2010.04.008","article-title":"Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients","volume":"92","author":"Grover","year":"2010","journal-title":"Biochimie"},{"key":"10.1016\/j.seizure.2018.04.006_bib0200","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1113\/jphysiol.2010.188482","article-title":"Sodium channel gene family: epilepsy mutations, gene interactions and modifier effects","volume":"588","author":"Meisler","year":"2010","journal-title":"J Physiol (Lond)"},{"key":"10.1016\/j.seizure.2018.04.006_bib0205","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/tpj.2013.43","article-title":"SCN1A variations and response to multiple antiepileptic drugs","volume":"14","author":"Yip","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.seizure.2018.04.006_bib0210","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/FPC.0b013e3283117d67","article-title":"Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression","volume":"18","author":"Kwan","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.seizure.2018.04.006_bib0215","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4103\/0028-3886.105191","article-title":"Lack of association between rs211037 of the GABRG2 gene and juvenile myoclonic epilepsy in Brazilian population","volume":"60","author":"Gitai","year":"2012","journal-title":"Neurol India"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131117307288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131117307288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:51:50Z","timestamp":1761011510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131117307288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":43,"alternative-id":["S1059131117307288"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2018.04.006","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of UGT2B7, SCN1A and CYP3A4 on the therapeutic response of sodium valproate treatment in children with generalized seizures","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2018.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}